Drug intelligence / Profile preview

glatiramer acetate + interferon beta-1a + interferon beta-1b

Development stage: Discontinued
Lead developer: Teva Pharmaceutical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Intramuscular

Overview

This is a combination of three separate disease-modifying therapies used for the treatment of relapsing forms of multiple sclerosis (MS). Each component works through different mechanisms to reduce inflammation and slow disease progression. These medications are typically used individually rather than as a fixed combination product. Studies have shown that combining interferon beta-1a with glatiramer acetate may not provide significant benefits over monotherapy.

Targets

MHC II (Major histocompatibility complex class II receptor)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on glatiramer acetate + interferon beta-1a + interferon beta-1b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glatiramer acetate + interferon beta-1a + interferon beta-1b.

Explore the full profile